Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients

Critical Care Medicine

Volumn 40, Issue 5, 2012, Pages 1478-1486

  Bruegel, Mathias ^a,c   Ludwig, Ute ^a   Kleinhempel, Alisa ^a   Petros, Sirak ^a   Kortz, Linda ^a,b   Ceglarek, Uta ^a,b   Holdt, Lesca Miriam ^a,b   Thiery, Joachim ^a,b   Fiedler, Georg Martin ^a,d  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Leipzig Interdisciplinary Research Cluster of Genetic Factors   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Arachidonic acid metabolites; eicosanoids; lipopolysaccharide; Sepsis; whole blood

Indexed keywords

11 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 2; HYDROXYICOSATETRAENOIC ACID; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LIQUID CHROMATOGRAPHY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ARACHIDONIC ACID; CHROMATOGRAPHY, LIQUID; DINOPROSTONE; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEPSIS; SHOCK, SEPTIC; TANDEM MASS SPECTROMETRY; THROMBOXANE B2; YOUNG ADULT;

EID: 84860245554     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182416f05     Document Type: Article

References (25)

1. Brock TG, Peters-Golden M: Activation and regulation of cellular eicosanoid biosynthesis. Sci World J 2007; 7:1273-1284
2. Tilley SL, Coffman TM, Koller BH: Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001; 108:15-23
3. Bulger EM, Maier RV: Lipid mediators in the pathophysiology of critical illness. Crit Care Med 2000; 28:N27-N36
4. Levy BD, Clish CB, Schmidt B, et al: Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2001; 2:612-619
5. Peplow PV: Actions of cytokines in relation to arachidonic acid metabolism and eicosanoid production. Prostaglandins Leukot Essent Fatty Acids 1996; 54:303-317
6. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-538
7. Kortz L, Geyer R, Ludwig U, et al: Simultaneous eicosanoid profiling and identification by liquid chromatography and hybrid triple quadrupole-linear ion trap mass spectrometry for metabolomic studies in human plasma. J Lab Med 2009; 3:341-348
8. Norris PC, Reichart D, Dumlao DS, et al: Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype. J Leukoc Biol 2011; 90:563-574
9. Opal SM, Scannon PJ, Vincent JL, et al: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584-1589
10. Nevalainen TJ: Serum phospholipases A2 in inflammatory diseases. Clin Chem 1993; 39:2453-2459
11. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. FASEB J. 1998; 12:1063-1073
12. Ishikawa T, Jain N, Herschman HR: Feedback regulation of Cyclooxygenase-2 transcription ex vivo and in vivo. BBRC 2009; 378:534-538
13. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
14. Ertel W, Kremer JP, Kenney J, et al: Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-1347
15. Harris SG, Padilla J, Koumas L, et al: Prostaglandins as modulators of immunity. Trends Immunol 2002; 23:144-150
16. Xu XJ, Reichner JS, Mastrofrancesco B, et al: Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production. J Immunol 2008; 180:2125-2131
17. Cipollone F, Cicolini G, Bucci M: Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008; 118:161-180
18. Suchner U, Katz DP, Furst P, et al: Impact of sepsis, lung injury, and the role of lipid infusion on circulating prostacyclin and thromboxane A(2). Intensive Care Med 2002; 28:122-129
19. Reines HD, Halushka PV, Cook JA, et al: Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 1982; 2:174-175
20. Yamada T, Fujino T, Yuhki K, et al: Thromboxane A2 regulates vascular tone via its inhibitory effect on the expression of inducible nitric oxide synthase. Circulation 2003; 108:2381-2386
21. Opal SM, DePalo VA: Anti-inflammatory cytokines. Chest 2000; 117:1162-1172
22. Celik I, Akbulut A, Kilic SS, et al: Effects of ibuprofen on the physiology and outcome of rabbit endotoxic shock. BMC Infect Dis 2002; 2:26
23. Bernard GR, Wheeler AP, Russell JA, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912-918
24. Shann F: Antipyretics in severe sepsis. Lancet 1995; 345:338
25. Biswas SK, Lopez-Collazo E: Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 2009; 30:475-487